Momenta Pharmaceuticals, Inc. (MNTA)

[mouton29]

USSC cert decision.

June is optimistic. If they follow the Classen sequence (see below) and ask the Solicitor General to file a brief, that can add months -- 6 in Classen. But you would think that, having given the matter some thought in Classen, that the SG would be a little quicker the second time around.

No. 11-1078
Title:
GlaxoSmithKline, Petitioner
v.
Classen Immunotherapies, Inc.
Docketed: March 1, 2012
Lower Ct: United States Court of Appeals for the Federal Circuit
Case Nos.: (2006-1634, 2006-1649)
Decision Date: August 31, 2011
Rehearing Denied: November 30, 2011

~~~Date~~~ ~~~~~~~Proceedings and Orders~~~~~~~~~~~~~~~~~~~~~
Feb 28 2012 Petition for a writ of certiorari filed. (Response due April 2, 2012)
Mar 29 2012 Brief amicus curiae of Pharmaceutical Research and Manufacturers of America filed.
Apr 17 2012 DISTRIBUTED for Conference of May 10, 2012.
Apr 23 2012 Response Requested . (Due May 23, 2012)
May 23 2012 Brief of respondent Classen Immunotherapies, Inc. in opposition filed.
Jun 4 2012 Reply of petitioner GlaxoSmithKline filed.
Jun 5 2012 DISTRIBUTED for Conference of June 21, 2012.
Jun 25 2012 The Solicitor General is invited to file a brief in this case expressing the views of the United States.
Dec 13 2012 Brief amicus curiae of United States filed.
Dec 26 2012 DISTRIBUTED for Conference of January 11, 2013.
Dec 26 2012 Supplemental brief of petitioner GlaxoSmithKline filed. (Distributed)
Jan 14 2013 Petition DENIED. Justice Alito took no part in the consideration or decision of this petition.